These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 21525152)

  • 1. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
    Duffy MJ
    Ann Clin Biochem; 2011 Jul; 48(Pt 4):310-6. PubMed ID: 21525152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSA in screening for prostate cancer: more good than harm or more harm than good?
    Duffy MJ
    Adv Clin Chem; 2014; 66():1-23. PubMed ID: 25344984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
    Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
    Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.
    Birnbaum JK; Feng Z; Gulati R; Fan J; Lotan Y; Wei JT; Etzioni R
    Cancer Epidemiol Biomarkers Prev; 2015 Apr; 24(4):677-82. PubMed ID: 25613117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current results on PSA-based prostate cancer detection].
    Graefen M; Schlomm T; Steuber T; Sauter G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The level of evidence for the use of biomarkers in the early detection of prostate cancer].
    Lamy PJ; Gauchez AS; Salomon L; Haugh M; Ceraline J; Fulla Y; Georges A; Larré S; Loric S; Luporsi E; Martin PM; Mazerolles C; Molinié V; Mongiat-Artus P; Piffret J; Thuillier F; Perrin P; Rebillard X;
    Ann Biol Clin (Paris); 2016; 74(2):227-32. PubMed ID: 27029727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen screening: pro.
    Loeb S; Catalona WJ
    Curr Opin Urol; 2010 May; 20(3):185-8. PubMed ID: 20224413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for prostate cancer with PSA testing: current status and future directions.
    Croswell JM; Kramer BS; Crawford ED
    Oncology (Williston Park); 2011 May; 25(6):452-60, 463. PubMed ID: 21717898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
    Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
    Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
    Mazzola CR; Ghoneim T; Shariat SF
    Prog Urol; 2011 Jan; 21(1):1-10. PubMed ID: 21193139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate specific antigen best practice statement: 2009 update.
    Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P
    J Urol; 2009 Nov; 182(5):2232-41. PubMed ID: 19781717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should prostate-specific antigen screening be offered to asymptomatic men?
    van Vugt HA; Bangma CH; Roobol MJ
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.
    Pienta KJ
    Urology; 2009 May; 73(5 Suppl):S11-20. PubMed ID: 19375622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
    Schmid M; Hansen J; Chun FK
    Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate specific antigen best practice statement: 2009 update.
    Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P;
    J Urol; 2013 Jan; 189(1 Suppl):S2-S11. PubMed ID: 23234625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unravelling the prostate-specific antigen controversy: a West of Scotland perspective.
    Zafar N; Miller S; Leburn V; Qureshi KN; Rajan P
    Scott Med J; 2014 May; 59(2):126-9. PubMed ID: 24682103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early detection, PSA screening, and management of overdiagnosis.
    Borza T; Konijeti R; Kibel AS
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1091-110, vii. PubMed ID: 24188254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.